Integra LifeSciences/$IART
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Integra LifeSciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
Ticker
$IART
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
4,396
ISIN
US4579852082
Website
IART Metrics
BasicAdvanced
$926M
-
-$0.38
1.27
-
Price and volume
Market cap
$926M
Beta
1.27
52-week high
$32.66
52-week low
$11.60
Average daily volume
1.3M
Financial strength
Current ratio
1.206
Quick ratio
0.572
Long term debt to equity
91.4
Total debt to equity
132.588
Interest coverage (TTM)
2.64%
Profitability
EBITDA (TTM)
340.766
Gross margin (TTM)
58.76%
Net profit margin (TTM)
-1.78%
Operating margin (TTM)
10.65%
Effective tax rate (TTM)
32.73%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
2.66%
Return on equity (TTM)
-1.85%
Valuation
Price to revenue (TTM)
0.562
Price to book
0.61
Price to tangible book (TTM)
-1.2
Price to free cash flow (TTM)
-35.88
Free cash flow yield (TTM)
-2.79%
Free cash flow per share (TTM)
-33.19%
Growth
Revenue change (TTM)
6.19%
Earnings per share change (TTM)
-174.44%
3-year revenue growth (CAGR)
1.38%
10-year revenue growth (CAGR)
7.58%
3-year earnings per share growth (CAGR)
-40.96%
10-year earnings per share growth (CAGR)
-4.56%
What the Analysts think about IART
Analyst ratings (Buy, Hold, Sell) for Integra LifeSciences stock.
Bulls say / Bears say
Integra LifeSciences reported a significant 11.5% increase in Q4 2024 revenues to $442.6 million, indicating strong demand for its products. (integra)
The successful integration of the Acclarent acquisition has expanded Integra's portfolio, potentially driving future growth. (integra)
The company has initiated a Compliance Master Plan to enhance quality management systems, aiming to improve operational efficiency and product reliability. (integra)
Despite revenue growth, Integra reported a GAAP loss of $(0.09) per share for 2024, reflecting operational challenges. (integra)
The company's net debt position of $1.5 billion and a leverage ratio of 4.0x may constrain financial flexibility. (integra)
Ongoing implementation of the Compliance Master Plan may lead to intermittent shipping holds, potentially impacting short-term revenues. (integra)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
IART Financial Performance
Revenues and expenses
IART Earnings Performance
Company profitability
IART News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
GlobeNewsWire·2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Accesswire·4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Integra LifeSciences stock?
Integra LifeSciences (IART) has a market cap of $926M as of June 20, 2025.
What is the P/E ratio for Integra LifeSciences stock?
The price to earnings (P/E) ratio for Integra LifeSciences (IART) stock is 0 as of June 20, 2025.
Does Integra LifeSciences stock pay dividends?
No, Integra LifeSciences (IART) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Integra LifeSciences dividend payment date?
Integra LifeSciences (IART) stock does not pay dividends to its shareholders.
What is the beta indicator for Integra LifeSciences?
Integra LifeSciences (IART) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.